IGC Pharma (IGC) Stock Statistics & Valuation Metrics

IGC Pharma has a market cap or net worth of $23.23M. The enterprise value is $29.90M.

Market Cap

$23.23M

Enterprise Value

$29.90M

IGC Pharma has 116,142,320 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

116,142,320

Owned by Insiders

10.96%

Owned by Institutions

2.90%

IGC Pharma’s return on equity (ROE) is -1.07 and return on invested capital (ROIC) is -144.79%.

Return on Equity (ROE)

-1.07

Return on Assets (ROA)

-0.71

Return on Invested Capital (ROIC)

-144.79%

Return on Capital Employed (ROCE)

-1.62

Revenue Per Employee

16.94K

Profits Per Employee

-93.54K

Employee Count

70

Asset Turnover

0.13

Inventory Turnover

1.31

The current PE Ratio of IGC Pharma is -2.43. IGC Pharma’s PEG ratio is 0.20.

PE Ratio

-2.43

PS Ratio

16.41

PB Ratio

3.37

Price to FCF

-3.95

Price to Operating Cash Flow

-4.20

PEG Ratio

0.20

In the last 12 months, IGC Pharma had revenue of 1.19M and earned -6.55M in profits. Earnings per share was -0.07.

Revenue

1.19M

Gross Profit

352.00K

Operating Income

-10.20M

Pretax Income

-6.55M

Net Income

-6.55M

EBITDA

-6.49M

Earnings Per Share (EPS)

-0.07

In the last 12 months, operating cash flow was -5.21M and capital expenditures -18,000, giving a free cash flow of -5.23M billion.

Operating Cash Flow

-5.21M

Free Cash Flow

-5.23M

Free Cash Flow per Share

-0.05

IGC Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-25.30%

Earnings Yield

-37.04%

Beta

0.71

52-Week Price Change

-48.05%

50-Day Moving Average

0.26

200-Day Moving Average

0.28

Relative Strength Index (RSI)

33.67

Average Volume (3m)

763.46K

IGC Pharma upcoming earnings date is ―, TBA (Confirmed).

Last Earnings Date

Jun 15, 2026

Next Earnings Date

―

Ex-Dividend Date

―

IGC Pharma as a current ratio of 0.40, with Debt / Equity ratio of 15.13%

Current Ratio

0.40

Quick Ratio

0.18

Debt to Market Cap

0.04

Net Debt to EBITDA

-0.11

Interest Coverage Ratio

0.00

In the past 12 months, IGC Pharma has paid 0 in taxes.

Income Tax

0

Effective Tax Rate

0.00

IGC Pharma EV to EBITDA ratio is -2.65, with an EV/FCF ratio of -3.88.

EV to Sales

16.11

EV to EBITDA

-2.65

EV to Free Cash Flow

-3.88

EV to Operating Cash Flow

-3.89

IGC Pharma has $377.00K in cash and marketable securities with $0.00 in debt, giving a net cash position of $377.00K billion.

Cash & Marketable Securities

$377.00K

Total Debt

$0.00

Net Cash

$377.00K

Net Cash Per Share

$0.00

Tangible Book Value Per Share

$0.01

Gross margin is 16.51%, with operating margin of -802.70%, and net profit margin of -643.65%.

Gross Margin

16.51%

Operating Margin

-802.70%

Pretax Margin

-643.65%

Net Profit Margin

-643.65%

EBITDA Margin

-608.25%

EBIT Margin

-469.21%

The average price target for IGC Pharma is $6.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target

$6.00

Price Target Upside

2900.00% Upside

Analyst Consensus

Moderate Buy

Analyst Count

1

Revenue Growth Forecast

―

EPS Growth Forecast

―

Smart Score

―

AI Score

44